Development of an Irreversible Peptidomimetic Radioligand for PET Imaging of ST14 Protease
Bioconjugate Chemistry · 15.01.2025 · 36 (1) · 116-126
DOI: 10.1021/acs.bioconjchem.4c00564 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, online erschienen am 02.01.2025. Verfasst von Tukang Peng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 2…. Hauptthemen laut MEDLINE: Peptidomimetics, Positron-Emission Tomography, Radiopharmaceuticals. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Shanghai Jiao Tong University, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
To enhance the affinity of peptide ligands for their targets, covalent warheads can be engineered to facilitate irreversible binding. This study aimed at exploring the potential of a 68 Ga-labeled peptidomimetic radioligand, [ 68 Ga]Ga-DOTA-RQAR-kbt, for PET imaging through its irreversible binding to the suppression of tumorigenicity 14 (ST14). An Arg-Gln-Ala-Arg (RQAR) tetrapeptide was conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid for gallium-68 radiolabeling. The covalent warhead ketobenzothiazole was constructed as a serine trap for ST14 protease, resulting in the formation of DOTA-RQAR-kbt. We compared both the in vitro and in vivo properties of [ 68 Ga]Ga-DOTA-RQAR-kbt with those of its reversible-binding counterparts, [ 68 Ga]Ga-DOTA-RQAR–OH. DOTA-RQAR-kbt exhibits high affinity for ST14 and irreversibly binds to ST14, as evidenced by the lack of ST14 activity recovery following ultrafiltration. In contrast, DOTA-RQAR–OH shows reversible binding and has low affinity for ST14. PET/CT imaging confirmed the superior tumor targeting of [ 68 Ga]Ga-DOTA-RQAR-kbt compared to the [ 68 Ga]Ga-DOTA-RQAR–OH, with robust signals observed at 0.5, 1, and 2 h postinjection. Blocking studies underscored the probe’s specificity, as they revealed a marked reduction in tumor uptake in the presence of excess RQAR-kbt. Biodistribution studies demonstrated significantly higher tumor uptake for [ 68 Ga]Ga-DOTA-RQAR-kbt, with 0.89 ± 0.03%ID/g at 1 h postinjection, which was reduced to 0.25 ± 0.03%ID/g ( P < 0.01) in the presence of excess RQAR-kbt. In this proof-of-concept study, an irreversibly binding peptidomimetic radioligand targeting ST14 was evaluated, demonstrating improved tumor uptake in vivo compared with its reversibly binding counterparts. This approach holds promise for improving the potency of covalent radiotracers as PET agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 210000, China.
- Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 210000, China.
ORCID-Profile: Jianjun Liu
Förderung
- Shanghai Jiao Tong University
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Peng, T., Huang, G., Zhao, H., & Liu, J. (2025). Development of an Irreversible Peptidomimetic Radioligand for PET Imaging of ST14 Protease. Bioconjugate Chemistry, 36(1), 116-126. https://doi.org/10.1021/acs.bioconjchem.4c00564
Vancouver
Peng T, Huang G, Zhao H, Liu J. Development of an Irreversible Peptidomimetic Radioligand for PET Imaging of ST14 Protease. Bioconjugate Chemistry. 2025;36(1):116-126. doi:10.1021/acs.bioconjchem.4c00564
BibTeX
@article{Peng2025,
author = {Peng, Tukang and Huang, Gang and Zhao, Haitao and Liu, Jianjun},
title = {Development of an Irreversible Peptidomimetic Radioligand for PET Imaging of ST14 Protease},
journal = {Bioconjugate Chemistry},
year = {2025},
volume = {36},
number = {1},
pages = {116--126},
doi = {10.1021/acs.bioconjchem.4c00564}
}
EUVIMED